EUCTR2006-003935-56-NL进行中（未招募）不适用
A clinical trial comparing treatment with cangrelor (in combinationwith usual care) to usual care, in subjects who require percutaneouscoronary intervention - Champion Platform
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 6,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or non-pregnant female at least 18 years of age
- •2. Diagnostic coronary angiography demonstrating atherosclerosis amenable to
- •treatment by PCI with or without stent implantation and one of the following:
- •2a. NSTEMI: Troponin I or T > upper limit of normal within 24-hours of randomization [or if troponin results are unavailable at that time, creatine kinase– myocardial band isoenzyme (CK-MB) > upper limit of normal]
- •2b. UA: Ischemic chest discomfort (angina or anginal equivalent) occurring at rest and lasting = 10 minutes within the 24 hours prior to randomization AND dynamic ECG changes† WITH either age= 65 years old and/or diabetes.
- •2c. STEMI: ECG changes including persistent [>20 minutes] ST-segment elevation in 2 or more contiguous leads)
- •3. Provide written informed consent before initiation of any study-related procedure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 . Planned staged PCI procedure where the second stage will occur = 30 days after
- •the first intervention
- •2 Admission planned for <12 hrs following PCI
- •3 Known or suspected pregnancy, or lactating females
- •4. Increased bleeding risk: ischemic stroke within the last year or any previous
- •hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial
- •aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery);
- •currently receiving warfarin, active bleeding
- •5. Impaired hemostasis: known International Normalized Ratio (INR) >1.5; past or
- •present bleeding disorder (including congenital bleeding disorders such as von
- •Willebrand’s disease or hemophilia, acquired bleeding disorders, and unexplained
- •clinically significant bleeding disorders), thrombocytopenia (platelet count
- •<100,000/µL), or history of thrombocytopenia or neutropenia associated with
- •clopidogrel
- •6. Severe hypertension not adequately controlled by antihypertensive therapy at the
- •time of randomization (systolic blood pressure>180 mm Hg or diastolic blood
- •pressure> 110 mm Hg)
- •7. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
- •8. Receipt of a clopidogrel dose exceeding the maintenance dose (ie, >75 mg) at any
- •time in the 5 days preceding randomization (subjects receiving chronic
- •clopidogrel therapy at a dose of 75 mg are eligible)
- •9. Not a candidate for PCI
- •10. Inability to swallow study capsules
- •11. Allergy, hypersensitivity, or contraindication to clopidogrel, cangrelor, mannitol,
- •sorbitol, or microcrystalline cellulose
- •12. Treatment with other investigational agents or devices within the 30 days
- •preceding randomization, planned use of investigational drugs or devices, or
- •previous enrollment in this trial
- •13. Known alcohol or illicit substance abuse
- •14. Inability to give informed consent or high likelihood of being unavailable for
- •15. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours
- •(applicable to UA and NSTEMI patients)
研究者
相似试验
进行中（未招募）
不适用
A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention - Champion PlatformSubjects with coronary atherosclerosis (excluding ST segment-elevationMI [STEMI]) who require PCI (with or without stent).MedDRA version: 9.1Level: LLTClassification code 10011093Term: Coronary atherosclerosisEUCTR2006-003935-56-ITTHE MEDICINES COMPANY UK6,400
已完成
3 期
A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary interventioAcute coronairy syndroomHeart diseases10028593NL-OMON30625Quintiles100
进行中（未招募）
1 期
A clinical trial comparing treatment with cangrelor (in combinationwith usual care) to usual care, in subjects who require percutaneouscoronary intervention - Champion PlatformSubjects with coronary atherosclerosis (excluding ST segment-elevationMI [STEMI]) who require PCI (with or without stent).MedDRA version: 8.1Level: LLTClassification code 10011093Term: Coronary atherosclerosisEUCTR2006-003935-56-SKThe Medicines Company6,400
进行中（未招募）
不适用
A clinical trial comparing treatment with cangrelor (in combinationwith usual care) to usual care, in subjects who require percutaneouscoronary intervention - Champion PlatformSubjects with coronary atherosclerosis (excluding ST segment-elevationMI [STEMI]) who require PCI (with or without stent).MedDRA version: 8.1Level: LLTClassification code 10011093Term: Coronary atherosclerosisEUCTR2006-003935-56-CZThe Medicines Company6,400
进行中（未招募）
不适用
A clinical trial comparing treatment with cangrelor (in combinationwith usual care) to usual care, in subjects who require percutaneouscoronary intervention - Champion PlatformEUCTR2006-003935-56-LTThe Medicines Company6,400